FDA slammed over Aduhelm OK as Biogen takes heat for $56k pr...

The FDA "has failed in its responsibility to protect patients and families from unproven treatments with known harms" in approving Biogen's Alzheimer's disease drug Aduhelm.

Amgen’s Enbrel heads ICER list of unjustified US price rises

US cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and concluded that seven of those were not backed by any clinical evidenc

What can Linux and Mozilla teach ICER about how to do drug v...

The Institute for Clinical and Economic Review (ICER) measures the value of new drugs and health technologies, but faces a number of key challenges such as keeping their assessments up to d

ICER methods could be illegal in US, claims US think tank

ICER says 'marginal' benefits for AbbVie's new RA drug

AbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as its mega-blockbuster Humira finally succumbs to cheaper biosimilar competit

Humira tops list of drugs with unwarranted US price hikes